Histology
Basal Cell Carcinoma
CI-CAN-00000479Explore in graph →
57 active trials4 approved drugs6 evidence items
Loading cancer entity…
Loading cancer entity…
Histology
CI-CAN-00000479Explore in graph →
Clinical trials
361 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (25)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05212246 | Basal Cell Carcinoma Chemoprevention Trial(B3C) | not yet recruiting | Phase 3 | 1,630 | VA Office of Research and DevelopmentFED | 1 | Sep 29, 2026 | clinicaltrials |
| NCT07144384 | Intratumoral Injection of Standard Universal Donor Expanded Natural Killer Cells and TGF-beta Imprinted Natural Killer Cells for the Treatment of Skin Squamous Cell Carcinoma and Basal Cell Carcinoma | completed | Early Phase 1 | 4 | Ohio State University Comprehensive Cancer CenterOTHER |
| 1 |
| Sep 28, 2026 |
| clinicaltrials |
| NCT04669808 | Open Label, Dose Escalation Study for the Safety and Efficacy of STP705 in Adult Patients With Basal Cell Carcinoma | completed | Phase 2 | 32 | SirnaomicsINDUSTRY | 1 | Sep 24, 2026 | clinicaltrials |
| NCT07182240 | Pilot Study of Line-Field Confocal Optical Coherence Tomography for Detection of Mohs Micrographic Surgery Margins of Basal Cell Carcinomas | recruiting | N/A | 60 | Roswell Park Cancer InstituteOTHER | 1 | Sep 24, 2026 | clinicaltrials |
| NCT07831083 | Skin Cancer Among Outdoor Workers(Skin Cancer Am) | completed | — | 10,000 | Assuta Medical CenterOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT06398418 | R-5780-01 In Combination With PD-1 Checkpoint Inhibitors (Checkpoint Protein on Immune Cells Called T Cells) in Patients With Solid Tumors | recruiting | Phase 1 | 33 | Rise Therapeutics LLCINDUSTRY | 1 | Sep 18, 2026 | clinicaltrials |
| NCT06422936 | Clinical Trial to Evaluate BO-112 in Patients With Basal Cell Carcinoma (BCC)(SPOTLIGHT204) | active not recruiting | Phase 2 | 50 | Highlight TherapeuticsINDUSTRY | 2 | Sep 17, 2026 | clinicaltrials |
| NCT07576725 | Low Dose, Reduced Frequency Nivolumab for the Treatment of Unresectable or Metastatic Cancer, AFFORD IO Trial | not yet recruiting | Phase 2 | 50 | Fred Hutchinson Cancer CenterOTHER | 1 | Sep 17, 2026 | clinicaltrials |
| NCT07808515 | A Study Comparing Cemiplimab-based Treatments for Adult Participants With Locally Advanced Basal Cell Skin Cancer (laBCC) | not yet recruiting | Phase 2 | 135 | Regeneron PharmaceuticalsINDUSTRY | 0 | Sep 9, 2026 | clinicaltrials |
| NCT07803406 | Multimodal Imaging of Basal Cell Carcinoma: A Usability Study | recruiting | — | 50 | Bispebjerg HospitalOTHER | 1 | Sep 3, 2026 | clinicaltrials |
| NCT05935995 | Intraoperative Assessment of Surgical Margins Using Confocal Microscopy in Comparison With Reference Extemporaneous Examination(HISTOBLOC) | completed | N/A | 42 | Institut de Cancérologie de LorraineOTHER | 1 | Sep 1, 2026 | clinicaltrials |
| NCT05896839 | Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer | recruiting | Phase 1 / Phase 2 | 16 | National Cancer Institute (NCI)NIH | 1 | Aug 31, 2026 | clinicaltrials |
| NCT06598137 | Study to Examine Lesions of the Skin Using Confocal Laser Microscopy | active not recruiting | — | 645 | LMU KlinikumOTHER | 1 | Aug 26, 2026 | clinicaltrials |
| NCT06600165 | Intraoperative Confocal Laser Scanning Microscopy With Use of AI for Optimized Surgical Excision of Basal Cell Carcinoma | recruiting | — | 1,000 | LMU KlinikumOTHER | 1 | Aug 26, 2026 | clinicaltrials |
| NCT07720726 | Impact of Dysport on PMFF Donor Scar | not yet recruiting | Phase 4 | 50 | Vanderbilt University Medical CenterOTHER | 1 | Aug 26, 2026 | clinicaltrials |
| NCT07786376 | AI in Histipathological Diagnosis of Bcc(AI\bcc) | not yet recruiting | — | 50 | Al-Azhar UniversityOTHER | 1 | Aug 26, 2026 | clinicaltrials |
| NCT04670445 | Improving Patient and Caregiver Understanding of Risks and Benefits of Immunotherapy for Advanced Cancer(UPLIFT) | completed | N/A | 199 | Massachusetts General HospitalOTHER | 1 | Aug 25, 2026 | clinicaltrials |
| NCT07682831 | Machine Learning Analysis of Two-photon Fluorescence Microscopy of Dermatologic Biopsies | recruiting | N/A | 92 | University of RochesterOTHER | 1 | Aug 19, 2026 | clinicaltrials |
| NCT07773688 | Two-photon Fluorescence Microscopy of Dermatologic Biopsies | recruiting | N/A | 644 | University of RochesterOTHER | 1 | Aug 19, 2026 | clinicaltrials |
| NCT07241585 | Vitamin D Effects on Immune Microenvironment of Nonmelanoma Skin Cancer After Photodynamic Therapy (PDT) | recruiting | N/A | 54 | Case Comprehensive Cancer CenterOTHER | 1 | Aug 18, 2026 | clinicaltrials |
| NCT02978625 | Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers | active not recruiting | Phase 2 | 68 | National Cancer Institute (NCI)NIH | 1 | Aug 13, 2026 | clinicaltrials |
| NCT05859074 | A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer | recruiting | Phase 1 | 56 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Aug 12, 2026 | clinicaltrials |
| NCT07600476 | A First-in-Human Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of KUP-101A in Patients With Selected Advanced Solid Tumors | recruiting | Phase 1 | 21 | Kupando GmbHINDUSTRY | 1 | Aug 12, 2026 | clinicaltrials |
| NCT05473507 | A Study of Observation and Follow-up in People With Basal Cell Carcinoma | active not recruiting | — | 26 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Aug 5, 2026 | clinicaltrials |
| NCT03816332 | Tacrolimus, Nivolumab, and Ipilimumab in Treating Kidney Transplant Recipients With Selected Unresectable or Metastatic Cancers | active not recruiting | Phase 1 | 12 | National Cancer Institute (NCI)NIH | 1 | Jul 31, 2026 | clinicaltrials |
| NCT07227350 | L19IL2 or L19TNF or L19IL2/TNF in Patients With Basal Cell Carcinoma (BCC) | recruiting | Phase 2 | 180 | Philogen S.p.A.INDUSTRY | 5 | Jul 31, 2026 | clinicaltrials |
| NCT07628634 | Feasibility Study on the Effect of a Methionine-Reduced Diet on Serum Levels in Pts w/ Solid Tumors | recruiting | Early Phase 1 | 25 | University of California, IrvineOTHER | 1 | Jul 31, 2026 | clinicaltrials |
| NCT06624475 | Neoadjuvant Nivolumab + Relatlimab (Opdualag) Versus Nivolumab for Resectable High-Risk Basal Cell Carcinoma(NEON) | recruiting | Phase 2 | 30 | University of California, San DiegoOTHER | 1 | Jul 28, 2026 | clinicaltrials |
| NCT04155190 | A Study of Patidegib Topical Gel, 2%, for the Reduction of Disease Burden of Persistently Developing Basal Cell Carcinomas in Patients With Non-Gorlin High Frequency BCC | terminated | Phase 2 | 50 | Sol-Gel Technologies, Ltd.INDUSTRY | 1 | Jul 21, 2026 | clinicaltrials |
| NCT07227870 | L19IL2/TNF in Patients With Basal Cell Carcinoma | recruiting | Phase 2 | 92 | Philogen S.p.A.INDUSTRY | 5 | Jul 21, 2026 | clinicaltrials |
| NCT05078047 | Study Comparing the Standard Administration of IO Versus the Same IO Administered Each 3 Months in Patients in Response After 6 Months of Standard IO(MOIO) | active not recruiting | Phase 3 | 646 | UNICANCEROTHER | 1 | Jul 17, 2026 | clinicaltrials |
| NCT07677124 | AI-Based Risk Classification and Histopathological Subtype Prediction of Basal Cell Carcinoma Using Dermoscopic Images(BCC-AI) | recruiting | — | 2,500 | Istanbul Training and Research HospitalOTHER_GOV | 1 | Jun 30, 2026 | clinicaltrials |
| NCT07670858 | Study of Intralesional FLD-103 in Subjects With Basal Cell Carcinoma (BCC) | recruiting | Phase 1 | 48 | Feldan TherapeuticsINDUSTRY | 2 | Jun 29, 2026 | clinicaltrials |
| NCT07670403 | Digital Phenotyping of Psychological Distress in Skin Cancer Patients(DP-SKIN) | completed | — | 500 | West China HospitalOTHER | 1 | Jun 26, 2026 | clinicaltrials |
| NCT07215988 | Studying Off Label Insurance Coverage for Patients With Cutaneous Cancers a "Filter" Observational Study | recruiting | — | 70 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Jun 25, 2026 | clinicaltrials |
| NCT04389112 | Study of Metabolic Changes in the Transformation Malignant Precancerous Skin Lesions(MITOSKIN) | completed | N/A | 119 | University Hospital, BordeauxOTHER | 1 | Jun 24, 2026 | clinicaltrials |
| NCT06539468 | Active Surveillance for the Treatment of Low-Risk Basal Cell Carcinoma in Elderly Patients | active not recruiting | N/A | 81 | University of Michigan Rogel Cancer CenterOTHER | 1 | Jun 23, 2026 | clinicaltrials |
| NCT07201012 | Determining the Prevalence of Muir-Torre Syndrome in Patients With Lynch Syndrome(SMT-SL) | recruiting | N/A | 150 | Centre Hospitalier Universitaire de NīmesOTHER | 1 | Jun 22, 2026 | clinicaltrials |
| NCT04552990 | Use of Jet-injection in Photodynamic Therapy for Basal Cell Carcinoma | completed | Phase 2 | 16 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jun 18, 2026 | clinicaltrials |
| NCT04616248 | In Situ Immunomodulation With CDX-301, Radiation Therapy, CDX-1140 and Poly-ICLC in Patients w/ Unresectable and Metastatic Solid Tumors | active not recruiting | Phase 1 | 14 | University of Southern CaliforniaOTHER | 1 | Jun 18, 2026 | clinicaltrials |
| NCT02834013 | Nivolumab and Ipilimumab in Treating Patients With Rare Tumors | active not recruiting | Phase 2 | 798 | National Cancer Institute (NCI)NIH | 2 | Jun 17, 2026 | clinicaltrials |
| NCT05929664 | Cemiplimab Plus Fianlimab for the Treatment of Locally Advanced Head and Neck Basal Cell Carcinoma Before Surgery | suspended | Phase 2 | 70 | Thomas Jefferson UniversityOTHER | 1 | Jun 10, 2026 | clinicaltrials |
| NCT04916002 | A Trial To Find Out If Vidutolimod Together With Cemiplimab Is Safe And If It Works In Adult Participants With Advanced Cancer Or Metastatic Cancer | terminated | Phase 2 | 77 | Regeneron PharmaceuticalsINDUSTRY | 2 | Jun 9, 2026 | clinicaltrials |
| NCT04806646 | Tailored Sonidegib Schedule After Complete Response in BCC(SONIBEC) | active not recruiting | Phase 2 | 21 | Gruppo Oncologico del Nord-OvestOTHER | 1 | Jun 1, 2026 | clinicaltrials |
| NCT05020912 | Alteration of the Immune Microenvironment in Basal Cell Carcinoma Following Photodynamic Therapy | active not recruiting | Phase 2 | 18 | Case Comprehensive Cancer CenterOTHER | 1 | Jun 1, 2026 | clinicaltrials |
| NCT06608511 | Liquid Biomarker Study in Melanoma and Non-Melanoma Skin Cancers | active not recruiting | — | 20 | University of Wisconsin, MadisonOTHER | 1 | May 29, 2026 | clinicaltrials |
| NCT06279143 | The Diagnostic Accuracy of Advanced Imaging in Identifying Suspected Skin Cancer (Basal Cell Carcinoma) Around the Eyes(dOCT-pBCC) | completed | — | 210 | Vejle HospitalOTHER | 1 | May 26, 2026 | clinicaltrials |
| NCT03610022 | Relationship Between Pharmacokinetics and Safety of Vismodegib - OPTIVISMO-1(OPTIVISMO-1) | completed | Phase 4 | 27 | University Hospital, BordeauxOTHER | 1 | May 19, 2026 | clinicaltrials |
| NCT00833417 | A Study Evaluating the Efficacy and Safety of Vismodegib (GDC-0449, Hedgehog Pathway Inhibitor) in Patients With Advanced Basal Cell Carcinoma | completed | Phase 2 | 104 | Genentech, Inc.INDUSTRY | 6 | May 11, 2026 | clinicaltrials |
Data updated 6 hours agoSource updated Sep 29, 2026source: clinicaltrials